Peptide Knowledge Base · Metabolic
5-Amino-1MQ: what it is, what the evidence says, and its real status
A non-peptide small-molecule NNMT inhibitor marketed for fat-cell metabolism, research-stage only.
Short version: not a peptide, a research-stage molecule sold online for fat metabolism, with no controlled human efficacy data. Education only; we capture the query and say what we don't know.
Can you actually get it?
Plain-English verdict: Education only.
Regulatory status: Research-only · Education only.
Not offered, education only. 5-Amino-1MQ is a research-stage NNMT inhibitor (not a peptide, not FDA-approved) with no controlled human efficacy data. We capture the query and make no weight-loss claim.
How does 5-Amino-1MQ work?
A small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase), proposed to shift fat-cell energy metabolism.
What it does — and what it does not do
What it does: Studied preclinically for fat-cell metabolism.
What it does not do: It is not a peptide, not proven in humans, and not a weight-loss treatment.
How honest is the evidence?
Evidence grade D — preclinical / animal-dominant; no controlled human efficacy data. Read our grading methodology for what each grade means.
What we still don't know: No credible controlled human evidence of meaningful fat loss; safety uncharacterized.
WADA status: Not prohibited.
How it is taken
Not offered; education only.
Who should not take it
Not characterized for human use; not a weight-loss treatment.
Sources
Preclinical NNMT-inhibition literature (animal-dominant)
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker or the knowledge base.
Last reviewed 2026-08-11 · Peptós.LIFE · Not medical advice.